现代肿瘤医学2010年4月第18卷第4期
周内、2周内乙肝病毒DNA量较治疗前的乙肝病毒DNA量降低值差异无显著性意义（P>0.05），第4周时其降低值差异具显著意义(P<0.05)。
研究组术后1周HBVDNA为
105.241.*，术后2周的乙肝病毒DNA为105.12±1.9，4周时为乙肝病毒DNA为10.9+1."，此说明短时间内拉米夫定可抑制乙肝病毒DNA复制，降低乙肝病毒DNA载量。
研究组Child分级和ALT在术后1周时、2周时与对照组相比略有改善，但差异无显著性意义(P>0.05），治疗4周后研究组ALT水平与对照组相比明显改善，说明拉米夫定短期内通过抑制乙肝病毒DNA复制面可减轻肝脏免疫损伤，改善肝功能。
微波消融已成为肝癌的主要治疗技术，疗效明确、创伤小、可反复操作，对原发性肝癌有较好的疗效，对小肝癌可取得根治性效果。乙肝病毒DNA阳性患者行手术切除及TA CE能激活乙肝病毒DNA复制，加重肝脏损伤，服用拉米夫定能有效抑制乙肝病毒复制，减轻肝损伤，提高生存率[9-10]；微波治疗术后应用拉米夫定，能抑制乙肝病毒复制，降低病毒载量，保护肝功能，能否提高患者生存期，有待进一步观察。
【参考文献】
王耀，陈涛，熊茂明，等，乙肝病毒在肝癌围手术期的防治[J][]
[2了[3][4][5]
[6][7][8]
[9][10]
肝服外科杂惠，2001,01：17-20
· 757 ·
郭震.肝介人治疗中拉米夫定的预防性应用J.包头医学院学报，2008,03:271273，
Beasley RP, Hepatitis B virus: the major etiology of hepatocellullar careinoma[J]. Cancer,1988,61(10) :1942.
彭文伟.传染病学[M].北京：人民卫生出版社，20-30.
孔丽，姚树坤，刘金星，等.原发性肝癌患者细胞免疫功能变化及其与转归的关系[J].中华肝脏病杂志,2005,13：194-197. 骆抗先.乙型肝炎基础与临床M].北京：人民卫生出版社， 2003;11.
杨春，肖永红，管小琴，等.拉米夫定治疗慢性乙型肝炎的临床观察及病理学研究[J].中华肝脏病杂志,2004，12(6)：264
Liaw YF. Prevention and surveillance of hepatitis B virus relasted hepatocellular carcinoma[ J]. Sem Liver Dis,2005 ,25 (1) ; 40 47.
王辉，区庆癌，陈涛，等.拉米夫定对肝癌围手术期乙肝病毒活联的防治研究[J].中国实用外科杂志，2001,21(2)：95-97. Nagamatsu H, Itano S, Nagaoka S, et al. Prolhylactie Lamivad ine administration prevents exacerbation of liver damagein HBean-tigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy [J], Am J Castroen-
terol,2004,99(12) ;2369.
氩氨刀联合肝动脉化疗栓塞术治疗原发性肝癌的临床研究
张
阳，梁宪斌，张丽红，曹
肠，张维真
编校：王
军）
EffectofcryotherapybyemployingArgon/HeliumsubsequentlycombinedwithTAcEon primaryhepaticcarcinoma
ZHANG Yang,LIANG Xian -bin,ZHANG Li -hong,CAO Yang,ZHANG Weizhen Department of Oncology,Third Peoples Hospital of Zhengzhou, Zhengzhou 450000, China.
Objective: To investigate the effect of cryotherapy of employing Argon/Helium subsequently combined
【Abstract]
with TACE for primary hepatic carcinoma. Methods: Forty cases with primary hepatic carcinoma received cryotherapy of employing Argon/Helium subsequently combined with TACE, One month after the combined treatment, AFP( alpha fetoprotein) and liver CECT( contrast enhancement computed tomography) and DSA were examined. The follow up time was 12 months. Results: In 83. 9% of patients with AFP level up to 400ng/ml, AFP value decreased more than 50% , Complete tumor necrosis was observed by liver CECT and DSA in 50. 0% ; incomplete necrosis in 27.5% ; part necrosis in 22. 5% . The 6 month and 12 month survival rates were 91. 0% and 76. 0% respectively without severe complications in the treatment. Conclusion : Subsequent combination of cryotherapy of employing Argon/Heli-um with TACE is an effective and safe therapy for primary hepatic carcinoma.
[ Key words] cryotherapy of employing Argon/Helium ; TACE : primary hepatic carcinoma
Modem Oncology 2010,18(04) :0757 0759
【收稿日期】【修回日期】【作者单位】【作者简介】
2009 06 10
2009 07 31
郑州市第三人民医院肿瘤内科，河南
南郑州
450000
张阳（1963-），女，河南南阳人，主任医师，主要从事肿瘤内科工作，侧重于恶性肿瘤的微创犯向消融治疗。E-mail：zhangyan-lin11@126. com